使用革兰氏阳性菌，比较通过Etest（AB生物梅里埃）和参考稀释法测定的达巴万星的最低抑菌浓度（MIC）值。
Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.
作者信息
Fritsche Thomas R, Rennie Robert P, Goldstein Beth P, Jones Ronald N
机构信息
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
出版信息
J Clin Microbiol. 2006 Aug;44(8):2988-90. doi: 10.1128/JCM.00640-06.
Abstract
While standardized microdilution testing methodologies and quality control ranges exist for the novel glycolipopeptide dalbavancin, no testing methods have been described that are immediately available for routine use in clinical laboratories. In this study, we found that the dalbavancin Etest (AB BIODISK, Solna, Sweden) procedure demonstrated a high degree of agreement (100% within +/-2 log(2) dilution steps) with the standardized broth microdilution method, validating the use of the Etest as an alternative test for investigational or clinical purposes following regulatory approval.
摘要
虽然新型糖肽类药物达巴万星有标准化的微量稀释测试方法和质量控制范围，但尚未有可立即用于临床实验室常规检测的方法被描述。在本研究中，我们发现达巴万星Etest（AB BIODISK，瑞典索尔纳）方法与标准化肉汤微量稀释法高度一致（在±2个对数2稀释步骤内为100%），这验证了在监管批准后，Etest可作为用于研究或临床目的的替代检测方法。
相似文献
1
Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.
J Clin Microbiol. 2006 Aug;44(8):2988-90. doi: 10.1128/JCM.00640-06.
2
Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.
Int J Antimicrob Agents. 2004 Feb;23(2):197-9. doi: 10.1016/j.ijantimicag.2003.07.008.
3
Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
J Clin Microbiol. 2006 Jul;44(7):2622-5. doi: 10.1128/JCM.00576-06.
4
Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.
J Clin Microbiol. 2007 Oct;45(10):3151-4. doi: 10.1128/JCM.02411-06. Epub 2007 Aug 1.
5
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Diagn Microbiol Infect Dis. 2005 Dec;53(4):307-10. doi: 10.1016/j.diagmicrobio.2005.03.004.
6
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
J Vis Exp. 2015 Sep 9(103):53028. doi: 10.3791/53028.
7
Validation and reproducibility assessment of tigecycline MIC determinations by Etest.
J Clin Microbiol. 2007 Aug;45(8):2474-9. doi: 10.1128/JCM.00089-07. Epub 2007 May 23.
8
In vitro activity of dalbavancin against enterococci isolates from wild animals, pets, poultry and humans in Portugal.
J Basic Microbiol. 2008 Dec;48(6):526-8. doi: 10.1002/jobm.200800146.
9
Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.
Diagn Microbiol Infect Dis. 2006 Feb;54(2):83-7. doi: 10.1016/j.diagmicrobio.2005.09.004.
10
Dalbavancin: a new option for the treatment of gram-positive infections.
Ann Pharmacother. 2006 Mar;40(3):449-60. doi: 10.1345/aph.1G158. Epub 2006 Feb 28.
引用本文的文献
1
Antimicrobial Susceptibility Testing for Enterococci.
J Clin Microbiol. 2022 Sep 21;60(9):e0084321. doi: 10.1128/jcm.00843-21. Epub 2022 Jun 13.
2
New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0261420. doi: 10.1128/aac.02614-20. Epub 2022 Apr 27.
3
Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.
Antibiotics (Basel). 2021 May 31;10(6):656. doi: 10.3390/antibiotics10060656.
4
Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
Emerg Microbes Infect. 2018 Dec 5;7(1):202. doi: 10.1038/s41426-018-0205-z.
5
Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.
Infect Dis Ther. 2016 Dec;5(4):535-544. doi: 10.1007/s40121-016-0133-y. Epub 2016 Oct 7.
6
Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).
Antimicrob Agents Chemother. 2016 May 23;60(6):3419-25. doi: 10.1128/AAC.00116-16. Print 2016 Jun.
7
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
J Vis Exp. 2015 Sep 9(103):53028. doi: 10.3791/53028.
8
History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.
Ther Clin Risk Manag. 2007 Dec;3(6):1143-52.
9
Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25.
10
Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.
J Clin Microbiol. 2007 Oct;45(10):3151-4. doi: 10.1128/JCM.02411-06. Epub 2007 Aug 1.
本文引用的文献
1
Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
J Chemother. 2005 Dec;17(6):593-600. doi: 10.1179/joc.2005.17.6.593.
2
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Diagn Microbiol Infect Dis. 2006 Feb;54(2):149-53. doi: 10.1016/j.diagmicrobio.2005.08.015. Epub 2006 Jan 19.
3
Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections.
Curr Opin Infect Dis. 2005 Dec;18(6):496-501. doi: 10.1097/01.qco.0000186850.54040.fc.
4
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Clin Infect Dis. 2005 Nov 15;41(10):1407-15. doi: 10.1086/497271. Epub 2005 Oct 6.
5
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Diagn Microbiol Infect Dis. 2005 Dec;53(4):307-10. doi: 10.1016/j.diagmicrobio.2005.03.004.
6
Origin, structure, and activity in vitro and in vivo of dalbavancin.
J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii15-20. doi: 10.1093/jac/dki005.
7
Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
Antimicrob Agents Chemother. 2005 Feb;49(2):770-2. doi: 10.1128/AAC.49.2.770-772.2005.
8
Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
J Antimicrob Chemother. 2004 Sep;54(3):617-20. doi: 10.1093/jac/dkh401. Epub 2004 Aug 20.
9
Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.
Int J Antimicrob Agents. 2004 Feb;23(2):197-9. doi: 10.1016/j.ijantimicag.2003.07.008.
10
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
Clin Infect Dis. 2003 Nov 15;37(10):1298-303. doi: 10.1086/379015. Epub 2003 Oct 17.
Zotero 插件